Pune, India, April 08, 2021 (GLOBE NEWSWIRE) -- Respiratory Drugs Market 2021 Size, Growth, Share, Cap, Regional Analysis With Global Industry Forecast To 2027. The rising adoption of innovative drugs for the treatment of various respiratory diseases is a key factor driving the global respiratory drugs, says Fortune Business Insights in a report, titled “Respiratory Drugs Market Size, Share & Industry Analysis, By Drug Class (Short-Acting Beta2-Agonists, Long-Acting Beta2-Agonists, Inhaled Corticosteroids, Anticholinergics, Antihistamines) By Disease Type (Asthma, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease, Pleural Effusion), By Route of Administration (Inhalation, Enteral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Fore.” The surge in R&D investments by major key players is expected to contribute significantly to the global respiratory diseases market.
As per the report, the rising prevalence of chronic obstructive pulmonary disease is expected to boost the global respiratory drugs market revenue during the forecast period. For instance, according to World Health Organization (WHO), in 2016 an estimate of 251 million cases of chronic obstructive pulmonary disease (COPD) were registered globally. It was further estimated that around 3.17 million deaths were caused by the disease globally.
Get Sample PDF Brochure of this Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/respiratory-drugs-market-101421
Out research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers & acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.
The report is focused on providing factual data. It briefly defines the current market scenario and offers key insights into the respiratory drugs market. It also provides information on various aspects of the market such as growth drivers, market restraint, market trends, industrial development, recent acquisitions and mergers.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/respiratory-drugs-market-101421
Rising Adoption of Sedentary Lifestyle Will Enable Growth
The increasing cases of respiratory infections around the world is expected to stimulate the growth of the global respiratory diseases market. The growing population and rising adoption of sedentary lifestyle will further create growth opportunities for the global respiratory drugs. The increasing exposure to air pollution and chemical occupational dust is predicted to encourage the growth of the global respiratory diseases market.
The surge in smokers around the world is also expected to fuel demand for innovative drugs, which, will, in, turn, accelerate growth of the global respiratory drugs. Furthermore, the FDA approval Tudorza® is expected to aid the global respiratory drugs growth. Circassia received FDA approval for the use of Tudorza® for the maintenance& treatment of chronic obstructive pulmonary disease (COPD).
Quick Buy - Respiratory Drugs Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101421
Moreover, Theravance Biopharma and Mylan N.V. received approval from FDA for New Drug Application (NDA) for YUPELRITM (revefenacin) inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). In addition, the presence of strong pipeline drugs is also predicted to contribute positively to the global respiratory diseases market.
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing. The financial parameters which are assessed include the sales, profits and the overall revenue generated by the key players of Market. Furthermore, the report offers a detailed analysis and information as per Respiratory Drugs Market Growth Analysis by manufacturers, market segments helping our readers to get a comprehensive overview of the global market. Several players are planning to focus on developing cost-effective products or services, aiming to maintain a strong foothold in the market.
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/queries/respiratory-drugs-market-101421
Presence Of Prominent Players Will Support Growth In North America
Geographically, the global respiratory drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Asia and Africa. North America is predicted to dominate the global respiratory drugs market during the forecast period owing to the presence of prominent market players in the U.S. and growing strategic partnerships among key players in launching of new products.
In Europe, the rising awareness about innovative respiratory drugs is expected to propel growth of the t respiratory drugs market in the region. Growing patient population and penetration of generic drugs for the treatment of various respiratory drugs is expected to boost the respiratory drugs market growth in Asia Pacific. In Middle East & Africa the unmet need for effective drugs for the treatment of respiratory diseases is likely to aid growth of the respiratory devices market during the forecast period
Some of The Major Companies That Are Present in The Global Respiratory Drugs Market Include:
- VAPOTHERM
- AptarGroup, Inc.
- Drägerwerk AG & CO.
- Allied Healthcare
- Cardinal Health
- NSPIRE HEALTH INC.
- oninklijke Philips N.V.
- and others
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/respiratory-drugs-market-101421
Market Segmentation:
By Drug Class
- Short-Acting Beta2-Agonists (SABA)
- Long-Acting Beta2-Agonists (LABA)
- Inhaled Corticosteroids (ICS)
- Anticholinergics
- Antihistamines
- Vasodilators
- Combination Drugs
- Others
By Disease Type
- Asthma
- Chronic Bronchitis
- Chronic Obstructive Pulmonary Disease (COPD)
- Pleural Effusion
- Others
By Route of Administration
- Inhalation
- Enteral
- Parenteral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Geography
- North America (the USA and Canada)
- Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America)
- Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)
Have a Look at Related Reports:
Wound Care Market Size, Share & Covid-19 Impact Analysis, By Type (Advanced Wound Dressing, Traditional Wound Care Products, Negative Pressure Wound Therapy, Bioactives, and Others), By Application (Chronic Wounds, and Acute Wounds), By End User (Hospitals, Clinics, Homecare Settings, and Others), and Regional Forecast, 2020-2027
Europe Prothrombin Complex Concentrate (PCC) Market Size, Share & Covid-19 Impact Analysis, By Product (4-factor PCC and 3-factor PCC), By Application (Acquired Coagulation Deficiency and Congenital Coagulation Deficiency and By End User (Hospitals & Ambulatory Surgical Centers, Specialty Clinics, and Others), 2020-2027
Anxiety Disorders and Depression Treatment Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents, and Atypical Antipsychotics), By Indication (Anxiety and Depression), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027
Multiple Sclerosis Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection (Intramuscular, Subcutaneous, and Intravenous) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Regional Forecast, 2020-2027
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs